Nutra Pharma Announces Initial Positive Safety Data From Clinical Study In Adrenomyeloneuropathy (AMN)

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis, has announced that its wholly-owned drug discovery subsidiary, ReceptoPharm, has reported initial positive safety data from its Phase IIb/IIIa clinical study of RPI-78M for treating Adrenomyeloneuropathy (AMN). RPI-78M is ReceptoPharm’s leading drug candidate for treating neurological and autoimmune disorders.

More: continued here

Filed under: Multiple Sclerosis on September 8th, 2008